TMC125-C216: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.
PHASE3CompletedINTERVENTIONAL
Enrollment
593
Participants
Timeline
Start Date
December 31, 2005
Primary Completion Date
January 31, 2007
Study Completion Date
July 31, 2008
Conditions
HIV
Interventions
DRUG
TMC125
2 x 100 mg tablets b.i.d. / 96 weeks
DRUG
Placebo
2 tablets b.i.d. / 96 weeks
All Listed Sponsors
lead
Tibotec Pharmaceuticals, Ireland
INDUSTRY
NCT00255099 - TMC125-C216: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options. | Biotech Hunter | Biotech Hunter